scholarly journals REDUCTION IN THE RISE OF SYSTOLIC BLOOD PRESSURE DURING HUMAN COITUS BY THE  -ADRENERGIC BLOCKING AGENT, PROPRANOLOL

Reproduction ◽  
1970 ◽  
Vol 22 (3) ◽  
pp. 587-590 ◽  
Author(s):  
C. A. FOX
Keyword(s):  
Blood Pressure ◽  
Systolic Blood Pressure ◽  
Blocking Agent ◽  
Adrenergic Blocking

Massive Clonidine Ingestion with Hypertension in a 9-Month-Old Infant

PEDIATRICS ◽  
1983 ◽  
Vol 72 (4) ◽  
pp. 500-502
Author(s):  
Pablo Yagupsky ◽  
Rafael Gorodischer
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Drugs ◽  
Complete Recovery ◽  
Blocking Agent ◽  
Assisted Ventilation ◽  
Antagonistic Effect ◽  
Arterial Blood ◽  
Clonidine Poisoning ◽  
Adrenergic Blockers ◽  
Adrenergic Blocking

The antihypertensive drug clonidine has a double and antagonistic effect on arterial blood pressure. As a result of activation of peripheral α-adrenergic receptors, it causes a transient increase in blood pressure; by a central action it decreases sympathetic tone which results in sustained bradycardia and hypotension. Both central and peripheral effects are experimentally blocked by tolazoline, an α-adrenergic blocking agent. The toxic symptoms seen in clonidine poisoning are usually produced by the central effect. A case of severe clonidine poisoning in a 9-month-old infant is reported. The clinical picture included coma, miosis, apneic spells, bradycardia, and hypertension. Rapid and complete recovery was obtained with supportive treatment that included assisted ventilation. No adrenergic blockers or antihypertensive drugs were given. Use of tolazoline in cases of clonidine overdose in children remains controversial. Supportive measures alone may be adequate for even the most severe cases.

scholarly journals Nebivolol for treatment patients with arterial hypertension

2014 ◽  
Vol 11 (3) ◽  
pp. 83-87
Author(s):  
O M Mikheeva ◽  
I A Komisarenko
Keyword(s):  
Blood Pressure ◽  
Arterial Hypertension ◽  
Oxidative Degradation ◽  
Blocking Agent ◽  
Blocking Effect ◽  
Beta Adrenergic ◽  
Adrenergic Blocking

Beta-adrenergic blocking agent is included in the group of primary agentsfor treatment of patients with AH. In the pathogenesis of AH,one of the main causes leading to raisingthe blood pressure isendothelial dysfunction.Correction ofendothelial dysfunctionis AH treatment strategic aim.Nebivololis a cardioselectivethird-generationvasodilatingβ-adrenergic blocking agent, which is in addition toβ-adrenergic blocking effect, can alsoincrease endogenousproduction of NOin the endothelial cellsdue to the decreasing of oxidative degradation. As a result,nebivololprovides positivehemodynamic effects on patients with AH, decreasingperipheral resistanceandblood pressure.

EFFECT OF TOLAZOLINE IN HEMORRHAGIC HYPOTENSION IN DOGS

1956 ◽  
Vol 34 (1) ◽  
pp. 951-958
Author(s):  
C. W. Gowdey ◽  
J. W. Pearce ◽  
J. A. F. Stevenson
Keyword(s):  
Blood Pressure ◽  
Hemorrhagic Shock ◽  
Blood Volume ◽  
Blocking Agent ◽  
Drug Induced ◽  
Hemorrhagic Hypotension ◽  
Blocking Agents ◽  
Adrenergic Blocking ◽  
Blood Reservoir ◽  
Adrenergic Blocking Agents

Adrenergic blocking agents have been found by several investigators to be beneficial in hemorrhagic shock under circumstances in which they can affect the volume of blood lost. In this study of the effect of the blocking agent tolazoline on the response to standardized hemorrhagic hypotension in the dog, in which a constant blood pressure is maintained by the reservoir method, no improvement in rate of survival was observed when an increase in blood volume in response to drug-induced vasodilatation was prevented. Nor did the stimulating effect of tolazoline on the heart improve survival, whether the drug was given during hypotension or at the time of reinfusion. When the blood reservoir was clamped off during the hypotensive period to prevent spontaneous changes in blood volume but not in blood pressure, the animals which were still able to increase their blood pressure survived after reinfusion whereas those which could not died, despite reinfusion of their original blood volume.

Slow-Release Oxprenolol Compared with Oxprenolol in Hypertensive Patients: A Multicenter Clinical Trial

1983 ◽  
Vol 17 (1) ◽  
pp. 51-54 ◽  
Author(s):  
Barry J. Materson ◽  
Basil A. Friedman ◽  
Khin Mae Hla ◽  
Barry S. Neidorf ◽  
James M. Gray ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Slow Release ◽  
Blocking Agent ◽  
Intrinsic Sympathomimetic Activity ◽  
Double Blind ◽  
Once Daily ◽  
Washout Phase ◽  
Blood Pressures ◽  
Adrenergic Blocking ◽  
Slow Release Preparation

Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50–100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg ( p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67) and 24/17 mm Hg ( p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

Pindolol: A Potent Beta-Adrenergic Blocking Agent in the Treatment of Hypertension

1978 ◽  
Vol 6 (6) ◽  
pp. 435-440 ◽  
Author(s):  
Nibha Jaroonvesma ◽  
Kawi Charoenlarp
Keyword(s):  
Blood Pressure ◽  
Combined Therapy ◽  
Blocking Agent ◽  
Efficacy And Safety ◽  
Beta Adrenergic ◽  
Hypertensive Patients ◽  
Significant Lowering ◽  
Treatment Of Hypertension ◽  
Adrenergic Blocking

Two groups of twenty-five hypertensive patients each were treated with a beta-adrenergic blocking agent (pindolol), either alone or in combination with classical antihypertensives. In the group under monotherapy a significant lowering of the blood pressure was observed. The effect was, however, not so consistent as in the group under combined therapy. The trial shows the efficacy and safety of pindolol in the treatment of hypertension mainly if applied in combination with a diuretic.

EFFECT OF TOLAZOLINE IN HEMORRHAGIC HYPOTENSION IN DOGS

1956 ◽  
Vol 34 (5) ◽  
pp. 951-958 ◽  
Author(s):  
C. W. Gowdey ◽  
J. W. Pearce ◽  
J. A. F. Stevenson
Keyword(s):  
Blood Pressure ◽  
Hemorrhagic Shock ◽  
Blood Volume ◽  
Blocking Agent ◽  
Drug Induced ◽  
Hemorrhagic Hypotension ◽  
Blocking Agents ◽  
Adrenergic Blocking ◽  
Blood Reservoir ◽  
Adrenergic Blocking Agents

Adrenergic blocking agents have been found by several investigators to be beneficial in hemorrhagic shock under circumstances in which they can affect the volume of blood lost. In this study of the effect of the blocking agent tolazoline on the response to standardized hemorrhagic hypotension in the dog, in which a constant blood pressure is maintained by the reservoir method, no improvement in rate of survival was observed when an increase in blood volume in response to drug-induced vasodilatation was prevented. Nor did the stimulating effect of tolazoline on the heart improve survival, whether the drug was given during hypotension or at the time of reinfusion. When the blood reservoir was clamped off during the hypotensive period to prevent spontaneous changes in blood volume but not in blood pressure, the animals which were still able to increase their blood pressure survived after reinfusion whereas those which could not died, despite reinfusion of their original blood volume.

Paradoxical Hypotension during Dobutamine Infusion for Myocardial Perfusion Scintigraphy

1998 ◽  
Vol 37 (08) ◽  
pp. 268-271
Author(s):  
B. Caner ◽  
E. Atalar ◽  
A. Karanfil ◽  
L. Tokgözoğlu ◽  
E. L. Ergün
Keyword(s):  
Blood Pressure ◽  
Myocardial Perfusion ◽  
Systolic Blood Pressure ◽  
Myocardial Perfusion Scintigraphy ◽  
Stress Test ◽  
Dobutamine Infusion ◽  
Perfusion Scintigraphy ◽  
Tilt Table ◽  
Study Results ◽  
Group A

Summary Aim: Dobutamine as a predominant beta-1 agonist increases heart rate and myocardial contractility and at sufficient high doses, it also increases systolic blood pressure. This study was undertaken to describe instances of paradoxical hypotension during dobutamine infusion for TI-201 myocardial perfusion SPECT study and the relationship between scintigraphic findings and hypotension occurred during dobutamine infusion. Methods: In 201 consecutive patients unable to perform adequate exercise, dobutamine TI-201 myocardial SPECT was performed. Dobutamine was infused starting from 10 μg/kg/min increasing to 40 μg/kg/min. Paradoxical hypotension was defined as a decrease in systolic blood pressure ≥ 20 mmHg compared with baseline study. Results: Paradoxical hypotension was observed in 40 patients (Group A) out of 201 (19.9%) while no significant change in systolic blood pressure was detected in the remaining 161 patients (Group B). Mean maximum fall in systolic blood pressure was 39 ± 18 mmHg (range: 20-90). In 33 of 40 patients (83%) with paradoxical hypotension, scintigraphy was normal compared to 131 (81%) of the remaining 161 patients. In patients of Group A, angiography, echocardiography and tilt table tests were performed in 13, 11 and 6 patients respectively. Nine of 13 angiographic evaluations (69%), 10 of 11 echocardiographic evaluations (91%), all of the tilt table tests were normal. Additionally, all of the patients of Group A were clinically followed up at least 6 months after the myocardial perfusion scintigraphy. None of the patients had a cardiac event except one patient during the follow-up period. Conclusion: Paradoxical hypotension during dobutamine infusion for myocardial scintigraphy is not an uncommon finding and up to 19.9% patients may develop such hypotension. To maximize test safety, precautions should be taken during dobutamine myocardial stress test, since remarkable decrease in systolic blood pressure may occur. Unlike hypotension occurring with exercise test, hypotension response to dobutamine is not always a marker for coronary artery disease.

Sign in / Sign up

Export Citation Format

Share Document